The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN)

Recruiting

• Conditions: Cardiometabolic Syndrome

• Registration Number: NCT06062836
• Lead Sponsor: National University Hospital, Singapore

Brief Summary

Background Changes in metabolism and mitochondrial function appear to precede cardiac dysfunction, with much evidence supporting metabolic dysregulation as one of the earliest precursors of cardiovascular disease. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) across National University Health System (NUHS) is a pilot, prospective, multi-ethnic cohort study in Singapore.

Through extensive phenotyping in a preventive cardiology cohort, the central aim is to define the metabolic flexibility range in a cohort of individuals at elevated risk of atherosclerotic cardiovascular disease, to correlate metabolic flexibility to measures of cardiometabolic health, including diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease.

Detailed Description

Aims

1. Define norms for metabolic flexibility in a multi-ethnic Southeast Asian cohort of individuals without manifest ASCVD

2. Understand the association of metabolic inflexibility with cardiovascular measures of diastolic dysfunction and coronary and cerebral atherosclerosis

3. Understand the association of metabolic inflexibility with measures of body fat distribution

4. Understand the correlation between metabolic flexibility and insulin sensitivity along the spectrum of subclinical cardiovascular disease and severity of non-alcoholic fatty liver disease

5. Associations of the gut microbiome as well as metabolomic and molecular markers with cardio-cerebrovascular measures, metabolic flexibility and liver fibrosis

The PICMAN study seeks to lay the foundations for further future larger scale and more experimentally ambitious studies based on the overarching hypothesis that metabolic flexibility is an early marker in subclinical cardiovascular disease, indicating a point of timely intervention where the disease process is still reversible. The importance of a deeply-phenotyped local cohort will allow us to study the progression of CVD in seemingly well adults, converging imaging, biochemical, metabolic markers, and 'omics analysis.

Study Timeline

• Study Start: 2022-04-01
• Status Verified: 2023-04
• Study First Submitted: 2023-04-10
• Study First Submitted QC: 2023-09-25
• Last Update Submitted: 2023-09-25
• Study First Posted: 2023-10-02
• Last Update Posted: 2023-10-02
• Primary Completion: 2023-12
• Study Completion: 2024-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Patients aged 21-70 at screening
• 10-year ASCVD risk > 5% measured by QRISK 3 calculator

Exclusion Criteria

• Established DM (Prior diagnosis, long term medications or HbA1c >=6.5)
• Established CVD, such as ischemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation
• Pregnancy
• Known contraindications to CT scan, such as allergy to contrast

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Metabolic flexibility	Up to 5 years	Metabolic flexibility will be calculated (deltaRQ)

Trial Locations

Locations (1)

National University Health System; 🇸🇬 Singapore, Singapore